Objective
TYPE 1 DIABETES
Edited by: Valentino Cherubini, Azienda Ospedaliero Universitaria Ospedali Riuniti, ItalyReviewed by: Siddharth Narayanan, Nationwide Children’s Hospital, United States; Leah Wilson, Oregon Health and Science University, United StatesThis article was submitted to Pediatric Endocrinology, a section of the journal Frontiers in EndocrinologyTo assess the efficacy and safety of a dual-hormone (DH [insulin and glucagon]) closed-loop system compared to a single-hormone (SH [insulin only]) closed-loop system in adolescents with type 1 diabetes.